Inhibition of RNA-binding protein HuR protected kidney from IR-induced injury and subsequent tubulointerstitial fibrosis via inhibiting inflammatory response and the majority of fibrotic pathways, suggesting that HuR-targeted inhibitory therapeutics offer a promising novel treatment for preventing or reversing the progression of CKD. Here, ELAVL1 is linked to chronic kidney disease.